Skip to main content
ENSC
NASDAQ Life Sciences

Ensysce Amends 8-K: Upsizes Cy Biopharma Deal Financing to $77M, Fixes Conversion Ratio

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.518
Mkt Cap
$7.959M
52W Low
$0.23
52W High
$2.75
52W Position info
125% above low
Off High info
81% below high
Rel. Volume info
32× avg
Market data snapshot near publication time

ENSC has more than doubled off its 52-week low of $0.23 on elevated volume (32× avg).

Summary

Ensysce's amended 8-K corrects the Series C conversion ratio and upsizes the Cy Biopharma acquisition financing to $77 million, providing critical runway but diluting existing holders to ~7.6% ownership.


Key Events · M&A and Partnerships · ENSC

  • Acquisition of Cy Biopharma

    Ensysce acquired Cy Biopharma in a stock-for-stock merger, issuing 282,122 shares of Series C Preferred Stock (convertible into 282.1M common shares) to Cy Biopharma equityholders, who will own ~75% of the combined company post-close.

  • Upsized Financing to $77M

    Total financing package increased to $77M: $21.5M initial private placement (66,811 Series C shares at $321.79/share), $17.1M cash from Cy Biopharma's pre-acquisition convertible notes, and up to $38.6M milestone tranche (53,449 shares at $402.24/share).

  • Extreme Dilution for Existing Holders

    Post-close, existing Ensysce shareholders will own only ~7.6% of the combined entity on a fully diluted basis (excluding milestone shares), with new investors holding ~17.5%.

  • Conversion Ratio Correction

    Amendment fixes a scrivener's error: each Series C Preferred share converts into 1,000 common shares, subject to stockholder approval under Nasdaq rules.


Analysis · ENSC · Life Sciences

This amendment to the original 8-K filed earlier today corrects a scrivener's error in the Series C Preferred Stock conversion ratio (now explicitly 1,000 common shares per preferred share) and upsizes the total financing package to $77 million — $21.5 million initial close, $17.1 million in Cy Biopharma cash, and up to $38.6 million in milestone-linked tranches. The corrected press release also reveals a higher fee to Tungsten Partners ($200,000 vs. $100,000). For a micro-cap company with a going-concern warning and Nasdaq delisting risk, this acquisition and financing pivot the entire investment thesis — the combined entity gains a clinical-stage neuroplastogenic therapy with FDA Orphan Drug Designation and a cash runway into 2028, but existing shareholders face extreme dilution (Cy Biopharma equityholders will own ~75% post-close).

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENSC was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENSC - Latest Insights

ENSC
Nov 12, 2026, 11:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.380
Real-time Price: $0.4343 info
Change: +$0.0543 (+14%) info
Market Cap: $8.141M info
ENSC
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.4343 info
Change: +$0.0472 (+12%) info
Market Cap: $8.141M info
ENSC
Nov 12, 2026, 4:17 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.4343 info
Change: +$0.0472 (+12%) info
Market Cap: $8.141M info
ENSC
Nov 12, 2026, 4:15 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.3871
Real-time Price: $0.4343 info
Change: +$0.0472 (+12%) info
Market Cap: $8.141M info
ENSC
Nov 04, 2026, 12:46 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3719
Real-time Price: $0.4343 info
Change: +$0.0624 (+17%) info
Market Cap: $8.141M info